Loading...
•
Jun 30, 2020
Matinas BioPharma Q2 2020 Earnings Report
Matinas BioPharma reported financial results for the second quarter ended June 30, 2020, along with a corporate update and outlook for 2020.
Key Takeaways
Matinas BioPharma announced that the ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed rapid enrollment after a temporary pause due to the COVID-19 pandemic. The company expects potential cohort progression in EnACT in the fourth quarter of this year and topline data from ENHANCE-IT in the first quarter of 2021.
ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021.
EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression Q4 2020.
Cash, cash equivalents and marketable securities at June 30, 2020 were approximately $68.0 million, compared to $27.8 million at December 31, 2019.
Net loss attributable to common shareholders was $5.8 million, or a net loss of $0.03 per share (basic and diluted).